Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PI3K/Akt/mTOR-IN-2 是一种有效的 PI3K/AKT/mTOR 抑制剂。PI3K/Akt/mTOR-IN-2 具有抗癌作用,并对 MDA-MB-231 细胞具有选择性,IC50 为 2.29 μM。PI3K/Akt/mTOR-IN-2 具有抗癌活性,可诱导癌细胞周期阻滞和细胞凋亡 (apoptosis)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 329 | 现货 | ||
5 mg | ¥ 788 | 现货 | ||
10 mg | ¥ 1,370 | 现货 | ||
25 mg | ¥ 2,870 | 现货 | ||
50 mg | ¥ 4,250 | 现货 | ||
100 mg | ¥ 5,930 | 现货 | ||
500 mg | ¥ 12,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 867 | 现货 |
产品描述 | PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor.PI3K/Akt/mTOR-IN-2 has anticancer effects and is selective for MDA-MB-231 cells with an IC50 of 2.29 μM.PI3K/Akt/mTOR-IN-2 exhibits anticancer activity and induces cycle arrest and apoptosis in cancer cells. PI3K/Akt/mTOR-IN-2 has anticancer activity and can induce cycle arrest and apoptosis in cancer cells. |
靶点活性 | PI3K/AKT/mTOR:2.29 μM |
体外活性 |
PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 h) demonstrates significant anti-cancer efficacy, with IC50 values ranging from 2.29 to 24.63 μM. Notably, its IC50 in MDA-MB-231 cells is 2.29 μM.[1] PI3K/Akt/mTOR-IN-2 (1, 2 and 4 μM; 24 h) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1.[1] PI3K/Akt/mTOR-IN-2 (1, 2, and 4 μM; 24, 48, and 72 h) elicits apoptosis in MDA-MB-231 cells in a manner that is both dose- and time-dependent.[1] PI3K/Akt/mTOR-IN-2 (1, 2, and 4 μM; 48 h) increases the expression of Bax and decreases the expression of Bcl-2 in MDA-MB-231 cells.[1] PI3K/Akt/mTOR-IN-2 (1, 2, and 4 μM; 24 h) triggers mitochondria-dependent apoptosis in MDA-MB-231 cells by perturbing mitochondrial membrane potential (MMP), causing an increase in reactive oxygen species (ROS), reducing intracellular glutathione (GSH) levels, and elevating intracellular calcium ion (Ca2+).[1] |
分子量 | 285.29 |
分子式 | C17H13F2NO |
CAS No. | 2757804-89-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 28.53 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.5052 mL | 17.526 mL | 35.0521 mL | 87.6301 mL |
5 mM | 0.701 mL | 3.5052 mL | 7.0104 mL | 17.526 mL | |
10 mM | 0.3505 mL | 1.7526 mL | 3.5052 mL | 8.763 mL | |
20 mM | 0.1753 mL | 0.8763 mL | 1.7526 mL | 4.3815 mL | |
50 mM | 0.0701 mL | 0.3505 mL | 0.701 mL | 1.7526 mL | |
100 mM | 0.0351 mL | 0.1753 mL | 0.3505 mL | 0.8763 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PI3K/Akt/mTOR-IN-2 2757804-89-8 Apoptosis Cytoskeletal Signaling PI3K/Akt/mTOR signaling Akt PI3K mTOR Inhibitor inhibitor inhibit